Management of Chronic Kidney Disease Stages 1–3
Clinical Bottom Line: Risk for Mortality in Patients With CKD Stages 1–3 Treated With Other Interventions
A low-strength body of evidence showed similar results for the risk of all-cause mortality between the following comparators: calcium channel blocker versus placebo; strict versus standard blood pressure-target treatment; gemfibrozil versus placebo; and dietary interventions. The strength of evidence for all comparators is low.
- Fink HA, Ishani A, Taylor BC, et al. Chronic Kidney Disease Stages 1–3: Screening, Monitoring, and Treatment. Comparative Effectiveness Review No. 37 (Prepared by the Minnesota Evidence-based Practice Center under Contract No. HHSA 290-2007-10064-I). Rockville, MD: Agency for Healthcare Research and Quality; January 2012. AHRQ Publication No. 11(12)-EHC075-EF. Available at www.effectivehealthcare.ahrq.gov/ckd.cfm.
Your slide tray is being processed.